# Botulinum Toxin in Pain Management

Contributor Information and Disclosures

Author

**Martin K Childers, DO, PhD**  Professor, Department of Neurology, Wake Forest University School of Medicine; Professor, Rehabilitation Program, Institute for Regenerative Medicine, Wake Forest Baptist Medical Center

Martin K Childers, DO, PhD is a member of the following medical societies: [American Academy of Physical Medicine and Rehabilitation](http://www.aapmr.org/), [American Congress of Rehabilitation Medicine](http://www.acrm.org/), [American Osteopathic Association](http://www.osteopathic.org/), [Christian Medical & Dental Society](http://www.cirtl.org/cmds.htm), and [Federation of American Societies for Experimental Biology](http://www.faseb.org/)

Disclosure: Allergan pharma Consulting fee Consulting

Specialty Editor Board

**Rajesh R Yadav, MD**  Associate Professor, Section of Physical Medicine and Rehabilitation, MD Anderson Cancer Center, University of Texas Medical School at Houston

Rajesh R Yadav, MD is a member of the following medical societies: [American Academy of Physical Medicine and Rehabilitation](http://www.aapmr.org/)

Disclosure: Nothing to disclose.

**Francisco Talavera, PharmD, PhD**  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

**Michael T Andary, MD, MS**  Professor, Residency Program Director, Department of Physical Medicine and Rehabilitation, Michigan State University College of Osteopathic Medicine

Michael T Andary, MD, MS is a member of the following medical societies: [American Academy of Physical Medicine and Rehabilitation](http://www.aapmr.org/), [American Association of Neuromuscular and Electrodiagnostic Medicine](http://www.aanem.org/), [American Medical Association](http://www.ama-assn.org/), and [Association of Academic Physiatrists](http://www.physiatry.org/)

Disclosure: Allergan Honoraria Speaking and teaching

**Kelly L Allen, MD**  Medical Director, Medevals

Disclosure: Nothing to disclose.

Chief Editor

**Consuelo T Lorenzo, MD**  Physiatrist, Department of Physical Medicine and Rehabilitation, Alegent Health Immanuel Rehabilitation Center

Consuelo T Lorenzo, MD is a member of the following medical societies: [American Academy of Physical Medicine and Rehabilitation](http://www.aapmr.org/)

Disclosure: Nothing to disclose.

**Overview**

Diagnosis and treatment of painful muscle syndromes can be a difficult and frustrating task for any clinician. Typically, the mainstay of therapy for such conditions is therapeutic exercise, analgesics, and a tincture of time. Unfortunately, not all patients respond to this paradigm, and, despite heroic efforts on the part of the treating clinician, some conditions are refractory to this approach.

Reports have described the purported effectiveness of using a biologic neuromuscular blocking agent, botulinum toxin, in the treatment of painful conditions associated with skeletal muscle. While incompletely understood and at times controversial, use of botulinum toxin in the treatment of conditions associated with involuntary muscle contraction, such as focal dystonia and spasticity, is supported by prospective, randomized clinical research; however, while the volume of comparable studies in pain syndromes is growing, the number of clinical randomized trials is limited. Moreover, not all such reports have demonstrated clear efficacy of the use of botulinum toxin under all circumstances. Therefore, in view of our current understanding of the nature of muscle-induced pain and the paucity of prospective research regarding neuromuscular blockade and/or inhibition of nociception in such conditions, critical and careful analysis of the data and opinions presented in this section is appropriate.

This article provides general direction and practical details for the clinician considering botulinum toxin for treatment of pain. Anatomic drawings for injection localization and dosing information are intended only as general guidelines; therapy with botulinum toxin always must be individualized, accounting for the patient's needs and the clinician's expertise. In addition, information presented should be used as a convenient reference source, not as a substitute for clinical training in the use of botulinum toxin.

For excellent patient education resources, visit eMedicine's [Muscle Disorders Center](http://www.emedicinehealth.com/collections/CO1551.asp) and [Procedures Center](http://www.emedicinehealth.com/Collections/SU304.asp). Also, see eMedicine's patient education articles [BOTOX® Injections](http://www.emedicinehealth.com/articles/40377-1.asp) and [Chronic Pain](http://www.emedicinehealth.com/articles/9239-1.asp).

**Pharmacology of Botulinum Toxin**

**Pharmacology**

Botulinum toxin is produced by the anaerobic bacterium *Clostridium botulinum*, a rod-shaped, gram-positive organism found in soil and water. Botulinum toxin type A (abbreviated BoNT-A or BTX-A) belongs to a family of neurotoxins (designated as types A, B, C1, C2, D, E, F, and G) with similar properties. BoNT-A causes degrees of flaccid (rather than rigid or tetanic) paralysis by blocking acetylcholine, required for muscle contraction, from release at the nerve terminal.[1, 2, 3] Therapeutic benefit may be derived by exploiting the pharmacologic properties of carefully administered regional application of this purified neurotoxin.

The various botulinum toxins possess individual potencies, and care is required to assure proper use and avoid medication errors. Recent changes to the established drug names by the FDA were intended to reinforce these differences and prevent medication errors. The products and their approved indications include the following:

* OnabotulinumtoxinA (Botox, Botox Cosmetic)
	+ Botox - Cervical dystonia, severe primary axillary hyperhidrosis, strabismus, blepharospasm
	+ Botox Cosmetic - Moderate-to-severe glabellar lines
* AbobotulinumtoxinA (Dysport) - Cervical dystonia, moderate-to-severe glabellar lines
* IncobotulinumtoxinA (Xeomin) - Cervical dystonia, blepharospasm
* Rimabotulinumtoxin B (Myobloc) - Cervical dystonia

Botulinum toxin's putative success in pain management was originally attributed to its ability to block acetylcholine from being released at the synapse. One important feature of botulinum toxin in pain treatment is that the neurotoxin is thought to act only on motor nerve endings while sparing sensory nerve fibers from its effects. Subsequently, however, effects of botulinum toxin on nociceptive neurons were demonstrated in preclinical studies.[4, 5, 6, 7] Thus, analgesic effects are likely to occur, but not as a consequence of blocking afferent sensory fibers at the site of injection; rather, they have been attributed to secondary effects that may be the result of muscle paralysis, improved blood flow, the release of nerve fibers under compression by abnormally contracting muscle, and, perhaps more importantly, the effects of the toxin on nociceptive neurons.

**Median lethal dose (LD50)**

Botulinum toxin's median lethal dose (LD50) has been determined across several animal species but not in humans. A unit of BoNT-A usually is defined in terms of its biologic potency. One mouse unit (MU) of BoNT-A equals the LD50 for a 20-g Swiss-Webster mouse. Yet BoNT-A sensitivity varies among different species. LD50 in monkeys has been determined as 39 U/kg. Based on these findings from primate studies, human LD50 is estimated at approximately 3000 U for a 70-kg adult. Typical doses for larger muscle groups range from 60-400 total units given in a single treatment; however, because of inadequate understanding of the complete dose response curve in humans, a relative ceiling dose of 360 U, given no sooner than 12 weeks apart, is recommended.

**Adverse effects**

Since the mechanism of action of BoNT-A is so specific, adverse effects are uncommon and systemic effects rare. Flulike syndrome has been reported, but it is generally short-lived. Other adverse effects have been reported, but they are not necessarily a result of BoNT-A treatment. They include muscle soreness, headaches, light-headedness, fever, chills, hypertension, weakness, diarrhea, and abdominal pain.

Muscular weakness, the predominant and desirable effect of botulinum toxin injection, also may be considered an adverse effect when weakness occurs in an unintended area or is greater than intended. Clinicians must understand the functional consequences of unintended weakness caused by botulinum toxin injection. While overweakening the muscles that curl the toes may have few, if any, undesirable consequences, spread of toxin into the muscles that control swallowing, which can occur when injecting muscles near the larynx (for instance, the proximal part of the sternocleidomastoid muscle), may result in difficulty swallowing. Patients, therefore, should be informed of the potential for either too much weakness in the injected area or weakness in nearby muscles.

**Use of Botulinum Toxin in Painful Neuromuscular Disorders**

Previous studies of conditions with involuntary muscular contractions have provided some indirect evidence of the analgesic effects of botulinum toxin. A summary of a MEDLINE search for clinical studies with the headings "botulinum toxin," and "pain" performed from 1966 to September 2005 resulted in more than 40 studies that included "pain" within the article title or abstract.

In the report, pain response to treatment with botulinum toxin was cited within the context of treatment for a number of conditions, including tennis elbow, chronic [anal fissure](http://emedicine.medscape.com/article/196297-overview), pain attributed to mastectomy and hemorrhoidectomy, [headaches](http://emedicine.medscape.com/article/792384-overview) (including [migraine](http://emedicine.medscape.com/article/1142556-overview)), piriformis syndrome, [facial pain](http://emedicine.medscape.com/article/1048596-overview), myofascial pain, [temporomandibular joint syndrome](http://emedicine.medscape.com/article/1143410-overview) (TMJ), [low back pain](http://emedicine.medscape.com/article/310353-overview), chronic prostatic pain, and whiplash.[8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]

Variables in these studies included dosing, concentration, injection techniques, use of concurrent therapeutic modalities, varying diagnoses, and chronicity of neurologic dysfunction. Some patients treated for disorders that included involuntary muscle contraction (eg, dystonia) also reported benefits in pain reduction in muscles injected with botulinum toxin. Variables in the studies cited included the presence or absence of concurrent therapy, diagnoses, length of time since onset of pain, dosing and concentration, and methodology for measurement of outcome.

Another review of botulinum toxin studies was performed by the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.[22] Evidence of the toxin's effectiveness was examined for a variety of conditions, including chronic tension-type headache, episodic [migraine](http://emedicine.medscape.com/article/1142556-overview), chronic daily [migraine](http://emedicine.medscape.com/article/1142556-overview), and chronic low back pain.

According to the subcommittee's report, the evidence indicated that botulinum toxin may be useful in the treatment of lower back pain but that it is probably not effective against episodic migraine and chronic tension-type headache. The report also stated that the available evidence was not strong or consistent enough to determine botulinum toxin's usefulness in the treatment of chronic daily headache (primarily, transformed migraine).

A German report also investigated botulinum toxin's effectiveness against tension-type headache.[23] In a double-blind, randomized, placebo-controlled study, researchers compared the number of headache-free days experienced by patients 4 weeks prior to injections of BoNT-A with the number of such days occurring 4-8 weeks after treatment. The number of headache-free days increased for the study's placebo and nonplacebo groups, but the difference in increase between the 2 groups was not significant.

The researchers did find, however, that in comparison with the placebo group, the patients who received BoNT-A injections experienced a significant reduction in the duration of their headaches.

**Botulinum Toxin and Myofascial Pain**

Many therapies are available to patients with myofascial pain syndrome. Much of the variation in forms of treatment (and diagnoses) of this disorder probably results from differences in culture, training, and recognition of an often undiagnosed syndrome of pain, dysfunction, and autonomic dysregulation. The etiology of myofascial pain syndrome associated with trigger points is incompletely understood. Some clinicians believe that it characteristically results from either an acute episode of muscle overload or from chronic and/or repetitive muscle overload. Active myofascial trigger points (MTrPs), which cause pain, exhibit marked localized tenderness and often refer pain to distant sites and disturb motor function. In addition, MTrPs may produce autonomic changes.

For clinical identification of MTrPs, the clinician palpates a localized tender spot in a nodular portion of a taut ropelike band of muscle fibers. Pressure over a trigger point elicits pain at that area and also may elicit pain at a site distant from the point under the fingertip (in a phenomenon known as referred pain). Upon palpation, MTrPs also elicit pain that mirrors the patient's experience. Applied pressure often evokes from the patient the response, "That's my pain!" Insertion of a needle, abrupt palpation, or even a brisk tap with the fingertip directly over the trigger point may result in a brief muscle contraction that is detectable by the examiner. This rapid contraction of muscle fibers of the ropelike taut band is termed a local twitch response.

In muscles that move a relatively small mass or are large and superficial (eg, finger extensors, gluteus maximus), the response is seen easily and may cause the limb to jump when the examiner introduces a needle into the trigger point. Localized abnormal response from the autonomic nervous system may cause piloerection, localized sweating, or regional temperature changes in the skin, attributed to altered blood flow.

Injection of muscles with botulinum toxin has been reported to be effective for myofascial pain caused by trigger points (TrPs) in a few small prospective studies. However, strong evidence of efficacy in larger, multicenter trials is lacking.[8, 24, 25]

**Botulinum Toxin and the Muscle Spindle: Clinical Issues**

Little evidence exists that painful muscle areas, such as TrPs, are associated with structural change or sensory structures, such as the muscle spindle; however, the spindle is intimately involved in certain conditions of abnormal muscle activity. In the spastic condition, for example, the stretch reflex is enhanced for a variety of reasons, such as lack of inhibition from spinal cord interneurons. Whatever the reason, muscle spindle physiology is an important regulator of muscle tone in the spastic condition.

BoNT-A has been recognized to reduce pain associated with various clinical conditions, including craniocervical dystonia, tension headaches, cervicogenic headaches, and migraine, an effect that has been observed independently of the toxin's effect on muscle relaxation. (As stated above, however, controversy exists regarding botulinum toxin's effectiveness in the treatment of headache.)[22, 23, 26, 27, 28, 29, 30]

Importantly, BoNT-A has been shown to inhibit release of neurotransmitters involved in pain transmission, including glutamate and substance P in rats. A formalin-induced pain model in rats has helped to show that a local peripheral injection of BoNT-A can significantly reduce glutamate release, signs of pain, and local edema without inducing muscle weakness. These preclinical observations have yet to be definitively confirmed in human patients; however, they provide a possible rationale for BoNT-A's use in chronic painful conditions, including chronic myofascial pain syndromes.

**When to Consider Botulinum Toxin**

Indications for botulinum treatment are not entirely clear for patients with myofascial pain syndrome. These patients may be considered candidates for botulinum toxin if they have not responded to traditional forms of treatment, have had a chronic refractory problem for 3 months or longer, have had a complete medical workup to rule out other nonmuscular causes for their pain, and have clearly defined TrPs.

The clinician should proceed with caution before considering using botulinum toxin in the treatment of a patient with myofascial pain. Remember that use of BoNT-A for the treatment of pain is only approved in the United States for pain related to cervical dystonia. Use of BoNT-A for myofascial pain, therefore, is an off-label use and may be considered most appropriate only for patients with a condition that does not respond to, or is judged inappropriate for, more conservative treatment. Factors that may identify a myofascial pain syndrome as potentially responding favorably to botulinum toxin injections include muscle hypertrophy, neurogenic and/or vascular compression, anatomic localization that isolates the target muscle from other structures, and more than 1 outcome measure to determine the efficacy of treatment. One such condition that meets these criteria is termed piriformis muscle syndrome (PMS).

**Botulinum Toxin Use in Piriformis Muscle Syndrome**

PMS is a controversial myofascial pain condition that presents with seemingly bizarre symptoms. Patients typically are female, have a recent history of trauma to the buttocks or pelvis (usually from a fall), and complain of deep pain in the buttocks and hip, radiating into the thigh or even into the leg and foot. These characteristic signs and symptoms may be from sciatic nerve compression by a contracted piriformis muscle as the nerve passes through the pelvis. Although some clinicians believe this diagnosis is controversial, several peer-reviewed articles cite clinical, anatomic, and electrophysiologic evidence for this distinct condition causing low back and leg pain.

On clinical examination, pressure over the buttocks at a point midway between the sacrum and greater trochanter of the hip reproduces the patient's pain complaint. Since the piriformis muscle is so deep, some clinicians say that palpation of this TrP can be performed properly only by rectal or vaginal examination. Palpation of the TrP on the posterolateral portion of the rectal (or vaginal) vault elicits pain at the site of compression and refers pain either into the thigh or down the leg.

The Beatty maneuver (see image below) also is a helpful clinical method of reproducing the patient's pain in this condition.[31] The patient is asked to lie on the nonpainful side and abduct the thigh by moving the painful leg off the table. This maneuver effectively contracts the piriformis muscle and should reproduce the patient's pain in the buttocks; however, since the syndrome essentially causes sciatic nerve compression at the level of the hip, other causes of sciatica should be ruled out (eg, herniated lumbar disc).

The Beatty maneuver.

One helpful diagnostic aid is electromyography. In a patient with radiculopathy and sciatica, an electromyographic examination should reveal abnormal spontaneous electrical activity in the extensor muscles of the back. In piriformis syndrome, the electromyogram (EMG) is classically normal. If there is enough sciatic nerve compression to cause axon loss, the abnormalities should be in the muscles distal to the piriformis, and no electrical activity should be seen in the back muscles. A special nerve conduction test, H reflex, has been reported to demonstrate abnormalities in piriformis syndrome when abduction, internal rotation, and flexion of the thigh compress the sciatic nerve; however, this result has not been reproduced by other clinicians. Making a reliable diagnosis in piriformis syndrome is almost impossible; thus, treatment also is difficult.

In some patients, if conservative treatment of piriformis syndrome fails, local injections of anesthetics and/or steroids should be considered. Surgical resection of the piriformis muscle is an additional option; however, some patients may gain short-term benefits from local TrP injections into the muscle without responding to other treatment for long-term pain control. This subset of patients may benefit from treatment with BoNT-A. (See image below.)

Left piriformis muscle, posterior view. Inject 100 U botulinum toxin type A (BOTOX®) diluted in 3 mL saline into the area marked with an 'X' when guided by fluoroscopy.

A limited number of studies assess the efficacy of botulinum toxin in the treatment of piriformis syndrome.[8] For example, Childers and colleagues reported findings from a double-blind placebo-controlled crossover pilot study of BoNT-A injection for refractory piriformis syndrome in 9 subjects.[32] All patients in this study reported pain intensity greater than 3/10 on visual analog pain scales (VASs) after at least 3 months of failed conservative treatment for PMS prior to enrollment. Symptomatic muscle in each patient was injected with 100 U BoNT-A or placebo (saline), using fluoroscopic and electromyographic guidance. Ten weeks later, saline or BoNT-A injections were repeated. The main outcome measures were VAS of pain intensity, distress, spasm, and interference with daily activities.

At baseline, no differences were detected between groups, yet significant (*P* < .05) differences were observed between the average of 2 minimum VAS at baseline and the average of 2 minimum VAS (in all categories) under the 10-week treatment (BoNT-A) arm, but not the 10-week placebo arm. In addition, BoNT-A treatment average was improved significantly (*P* = .0273), from baseline/washout average in VAS of daily activities. Data also suggested that a significant (*P* = .0547) improvement in VAS in muscle spasm (*P* = .0547) occurred in the BoNT-A group but not in the placebo group. Taken together, these findings demonstrated that, compared to intramuscular saline, BoNT-A injections reduced some, but not all, reports of pain attributed to chronic PMS.

**Injection Methods**

Therapy with botulinum toxin should be individualized for the patient and the clinician. The equipment needs should be determined according to the needs of the patient, the clinician's training, and the anatomic target for injection. For example, treatments for blepharospasm usually are given by simple subcutaneous injections around the eye without the use of special equipment; however, injections into the deep compartments of the low back, such as the psoas major muscle compartment, may require the use of special imaging techniques.

A 1.0 mL tuberculin-type syringe with 5/8-inch 25-gauge needle is adequate for superficial muscles. For small muscles (eg, facial muscles), a 1-inch 30-gauge needle is sufficient. For larger muscles, such as the hamstrings, a 1-inch or 1.5-inch 25-gauge needle is adequate.

For most limb muscles, the use of electromyography or motor point stimulation (e-stim) is recommended to identify muscles, particularly the smaller muscles in the forearm. For example, a commonly injected finger flexor muscle, the flexor digitorum sublimis (FDS), is nearly impossible to locate without electromyographic guidance. For the clinician who is developing his or her skills in identifying specific muscles for injection with botulinum toxin, the use of simple, audio-only electromyography may enhance the clinician's understanding of functional anatomy and aid the clinician in making decisions on injection localization. For muscles requiring electromyographic guidance, a cannulated monopolar needle cathode, through which botulinum toxin can be injected, is used. Surface reference (anode) and ground electrodes should be placed near the cathode needle.

After placing the patient in a position where the desired muscle can be relaxed, the motor point should be located. Botulinum toxin then can be given after aspiration to prevent intravascular injection. Alcohol, if used to clean the skin, should be allowed to dry completely to prevent toxin deactivation. The use of operating rooms or special procedure (sterile) rooms equipped with monitoring devices for the purpose of intramuscular injections using small caliber needles is not necessary. Most patients can be treated safely in an office setting by experienced clinicians.

**Postinjection Follow-up**

If any discomfort or pain occurs over 24-48 hours after injection, muscle relaxants or acetaminophen may be given. Stronger analgesics usually are not required.

Read more about Botulinum Toxin in Pain Management on Medscape

|  |  |
| --- | --- |
| Related Reference Topics* [Therapeutic Injections for Pain Management](http://emedicine.medscape.com/article/1143675-overview)
* [Botulinum Toxin](http://emedicine.medscape.com/article/325451-overview)
* [Dermatologic Use of Botulinum Toxin](http://emedicine.medscape.com/article/1126453-overview)
 | Related News and Articles* [Botulinum Toxin for Painful Spasms From Focal Seizures](http://emedicine.medscape.com/viewarticle/778500)
* [Repeat Botox Shots Appear Safe, Effective for Bladder Pain Syndrome](http://emedicine.medscape.com/viewarticle/776969)
* [Botulinum Toxin A for Chronic Migraine?](http://emedicine.medscape.com/viewarticle/765180)
 |

About Medscape Reference

**Information from Industry**

[Do your relapsing MS patients need a support service they can call day or night?](http://as.webmd.com/event.ng/Type%3Dclick%26FlightID%3D381383%26AdID%3D663844%26TargetID%3D132863%26Values%3D60%2C72%2C85%2C91%2C145%2C150%2C205%2C208%2C222%2C229%2C236%2C250%2C308%2C309%2C339%2C427%2C612%2C1469%2C1965%2C2006%2C2667%2C3175%2C3187%2C3221%2C3432%2C3438%2C3443%2C6843%2C13858%2C14128%2C14130%2C15191%2C18257%2C18924%2C19407%2C20184%2C20835%2C24347%2C24977%2C25585%2C25659%2C26513%2C26575%2C31795%2C31912%2C31919%2C43128%2C49066%2C49544%2C51406%2C53481%2C53875%26Redirect%3Dhttp%3A/www.medscape.com/infosite/rebif/article-4?src=ad_txt)

[Learn about MS LifeLines®](http://as.webmd.com/event.ng/Type%3Dclick%26FlightID%3D381383%26AdID%3D663844%26TargetID%3D132863%26Values%3D60%2C72%2C85%2C91%2C145%2C150%2C205%2C208%2C222%2C229%2C236%2C250%2C308%2C309%2C339%2C427%2C612%2C1469%2C1965%2C2006%2C2667%2C3175%2C3187%2C3221%2C3432%2C3438%2C3443%2C6843%2C13858%2C14128%2C14130%2C15191%2C18257%2C18924%2C19407%2C20184%2C20835%2C24347%2C24977%2C25585%2C25659%2C26513%2C26575%2C31795%2C31912%2C31919%2C43128%2C49066%2C49544%2C51406%2C53481%2C53875%26Redirect%3Dhttp%3A/www.medscape.com/infosite/rebif/article-4?src=ad_txt)





<script type="text/javascript" language="JavaScript1.2" src="http://as.medscape.com/js.ng/params.richmedia%3Dyes&amp;transactionid%3D7993407685&amp;pos%3D125&amp;pf%3D10&amp;usp%3D47&amp;occ%3D0&amp;tid%3Dt1477\_0t&amp;tcid%3D\_&amp;auth%3D1&amp;ct%3Dru&amp;inst%3D0&amp;kw%3D0&amp;artid%3Dckb325574&amp;pub%3D0&amp;spon%3D0&amp;st%3D0&amp;env%3D0&amp;ssp%3D46&amp;cg%3D503&amp;pclass%3Dcontent&amp;scg%3D3003375&amp;bc%3D\_r52\_r529\_&amp;valid%3D&amp;affiliate%3D2&amp;site%3D1&amp;leaf%3D0&amp;tile%3D5576745905"></script>

<script type="text/javascript" language="JavaScript1.2" src="http://as.medscape.com/js.ng/params.richmedia%3Dyes&amp;transactionid%3D7993407685&amp;pos%3D141&amp;pf%3D10&amp;usp%3D47&amp;occ%3D0&amp;tid%3Dt1477\_0t&amp;tcid%3D\_&amp;auth%3D1&amp;ct%3Dru&amp;inst%3D0&amp;kw%3D0&amp;artid%3Dckb325574&amp;pub%3D0&amp;spon%3D0&amp;st%3D0&amp;env%3D0&amp;ssp%3D46&amp;cg%3D503&amp;pclass%3Dcontent&amp;scg%3D3003375&amp;bc%3D\_r52\_r529\_&amp;valid%3D&amp;affiliate%3D2&amp;site%3D1&amp;leaf%3D0&amp;tile%3D5576745905"></script>

* [About Medscape](http://www.medscape.com/public/about)
* [Privacy Policy](http://www.medscape.com/public/privacy)
* [Terms of Use](http://www.medscape.com/public/termsofuse)
* [WebMD](http://www.webmd.com)
* [MedicineNet](http://www.medicinenet.com/)
* [eMedicineHealth](http://www.emedicinehealth.com)
* [RxList](http://www.rxlist.com)
* [WebMD Corporate](http://www.wbmd.com)
* [Help](http://www.medscape.com/public/help)
* [Contact Us](http://www.medscape.com/px/contactus)

All material on this website is protected by copyright, Copyright © 1994-2013 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.

1. Coffield JA, Considine RB, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M, eds. Therapy With Botulinum Toxin. New York, NY: Marcel Dekker; 1994:3-14.
2. Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: nature and preparation for clinical use. Eye. 1988;2 ( Pt 1):16-23. [[Medline]](http://reference.medscape.com/medline/abstract/3410136).
3. Sellin LC. The action of botulinum toxin at the neuromuscular junction. Med Biol. Feb 1981;59(1):11-20. [[Medline]](http://reference.medscape.com/medline/abstract/6115105).
4. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S125-32. [[Medline]](http://reference.medscape.com/medline/abstract/12569959).
5. Blersch W, Schulte-Mattler WJ, Przywara S, et al. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. Dec 15 2002;205(1):59-63. [[Medline]](http://reference.medscape.com/medline/abstract/12409185).
6. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. Feb 2004;251 Suppl 1:I1-7. [[Medline]](http://reference.medscape.com/medline/abstract/14991335).
7. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1:S9-15. [[Medline]](http://reference.medscape.com/medline/abstract/12887389).
8. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting--a review of the literature. Pain Pract. Jul-Aug 2008;8(4):269-76. [[Medline]](http://reference.medscape.com/medline/abstract/18503628).
9. Colak T, Ipek T, Kanik A, Aydin S. A randomized trial of botulinum toxin vs lidocain pomade for chronic anal fissure. Acta Gastroenterol Belg. Oct-Dec 2002;65(4):187-90. [[Medline]](http://reference.medscape.com/medline/abstract/12619423).
10. Davies J, Duffy D, Boyt N, et al. Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study. Dis Colon Rectum. Aug 2003;46(8):1097-102. [[Medline]](http://reference.medscape.com/medline/abstract/12907905).
11. Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. Oct 2000;38(5):466-71. [[Medline]](http://reference.medscape.com/medline/abstract/11010775).
12. Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache. Nov-Dec 2002;42(10):1033-7. [[Medline]](http://reference.medscape.com/medline/abstract/12453036).
13. Girdler NM. Use of botulinum toxin to alleviate facial pain. Br J Hosp Med. Oct 5-18 1994;52(7):363. [[Medline]](http://reference.medscape.com/medline/abstract/7858823).
14. Godevenos D, Pikoulis E, Pavlakis E, et al. The treatment of chronic anal fissure with botulinum toxin. Acta Chir Belg. Oct 2004;104(5):577-80. [[Medline]](http://reference.medscape.com/medline/abstract/15571027).
15. Johnstone SJ, Adler CH. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache. May 1998;38(5):366-8. [[Medline]](http://reference.medscape.com/medline/abstract/9630789).
16. Layeeque R, Hochberg J, Siegel E, et al. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg. Oct 2004;240(4):608-13; discussion 613-4. [[Medline]](http://reference.medscape.com/medline/abstract/15383788). [[Full Text]](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356462/).
17. Minguez M, Melo F, Espi A, et al. Therapeutic effects of different doses of botulinum toxin in chronic anal fissure. Dis Colon Rectum. Aug 1999;42(8):1016-21. [[Medline]](http://reference.medscape.com/medline/abstract/10458124).
18. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. Oct 2002;99(3):465-73. [[Medline]](http://reference.medscape.com/medline/abstract/12406522).
19. von Lindern JJ. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg. Mar 2001;101(1):39-41. [[Medline]](http://reference.medscape.com/medline/abstract/11379274).
20. von Lindern JJ, Niederhagen B, Bergé S, et al. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. Jul 2003;61(7):774-8. [[Medline]](http://reference.medscape.com/medline/abstract/12856249).
21. Wollina U, Konrad H. Botulinum toxin A in anal fissures: a modified technique. J Eur Acad Dermatol Venereol. Sep 2002;16(5):469-71. [[Medline]](http://reference.medscape.com/medline/abstract/12428839).
22. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. May 6 2008;70(19):1707-14. [[Medline]](http://reference.medscape.com/medline/abstract/18458231).
23. Straube A, Empl M, Ceballos-Baumann A, et al. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol. Mar 2008;15(3):205-13. [[Medline]](http://reference.medscape.com/medline/abstract/18290842).
24. Guarda-Nardini L, Stecco A, Stecco C, Masiero S, Manfredini D. Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique. Cranio. Apr 2012;30(2):95-102. [[Medline]](http://reference.medscape.com/medline/abstract/22606852).
25. Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. Curr Pain Headache Rep. Oct 2012;16(5):413-22. [[Medline]](http://reference.medscape.com/medline/abstract/22777564).
26. Mathew NT. Dynamic optimization of chronic migraine treatment: current and future options. Neurology. Feb 3 2009;72(5 Suppl):S14-20. [[Medline]](http://reference.medscape.com/medline/abstract/19188563).
27. Obermann M, Diener HC. Is botulinum toxin useful in treating headache? No. Curr Treat Options Neurol. Jan 2009;11(1):24-31. [[Medline]](http://reference.medscape.com/medline/abstract/19094833).
28. Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol. Jan 2009;11(1):18-23. [[Medline]](http://reference.medscape.com/medline/abstract/19094832).
29. Aguggia M. Treating headaches with botulinum toxin. Neurol Sci. May 2008;29 Suppl 1:S137-9. [[Medline]](http://reference.medscape.com/medline/abstract/18545915).
30. Frampton JE. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs. Apr 16 2012;72(6):825-45. [[Medline]](http://reference.medscape.com/medline/abstract/22468643).
31. Beatty RA. The piriformis muscle syndrome: a simple diagnostic maneuver. Neurosurgery. Mar 1994;34(3):512-4; discussion 514. [[Medline]](http://reference.medscape.com/medline/abstract/8190228).
32. Childers MK, Wilson DJ, Gnatz SM, et al. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil. Oct 2002;81(10):751-9. [[Medline]](http://reference.medscape.com/medline/abstract/12362115).
33. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology. Mar 1994;80(3):705-6. [[Medline]](http://reference.medscape.com/medline/abstract/8141474).
34. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. Apr 2007;47(4):486-99. [[Medline]](http://reference.medscape.com/medline/abstract/17445098).
35. Barwood S, Baillieu C, Boyd R, et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol. Feb 2000;42(2):116-21. [[Medline]](http://reference.medscape.com/medline/abstract/10698329).
36. Bickerton LE, Agur AM, Ashby P. Flexor digitorum superficialis: locations of individual muscle bellies for botulinum toxin injections. Muscle Nerve. Aug 1997;20(8):1041-3. [[Medline]](http://reference.medscape.com/medline/abstract/9236799).
37. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. Dec 2000;123(6):669-76. [[Medline]](http://reference.medscape.com/medline/abstract/11112955).
38. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. Aug 2001;10(8):1531-44. [[Medline]](http://reference.medscape.com/medline/abstract/11772268).
39. Borodic GE, Ferrante R, Pearce LB, et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. Jan 1994;9(1):31-9. [[Medline]](http://reference.medscape.com/medline/abstract/8139603).
40. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. Oct 1994;59(1):65-9. [[Medline]](http://reference.medscape.com/medline/abstract/7854804).
41. Childers MK. Rationale for injection procedures for botulinum toxin type A in skeletal limb muscles. Eur J Neurol. 1997;4(Suppl 2):37-40.
42. De Andrés J, Cerda-Olmedo G, Valía JC, et al. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain. Jul-Aug 2003;19(4):269-75. [[Medline]](http://reference.medscape.com/medline/abstract/12840622).
43. de Paiva A, Ashton AC, Foran P, et al. Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease. J Neurochem. Dec 1993;61(6):2338-41. [[Medline]](http://reference.medscape.com/medline/abstract/8245989).
44. Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am J Phys Med Rehabil. Dec 2002;81(12):936-42. [[Medline]](http://reference.medscape.com/medline/abstract/12447093).
45. Fishman LM, Zybert PA. Electrophysiologic evidence of piriformis syndrome. Arch Phys Med Rehabil. Apr 1992;73(4):359-64. [[Medline]](http://reference.medscape.com/medline/abstract/1554310).
46. Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. May 22 2001;56(10):1290-3. [[Medline]](http://reference.medscape.com/medline/abstract/11376175).
47. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. Apr 2003;4(3):159-65. [[Medline]](http://reference.medscape.com/medline/abstract/14622713).
48. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol. Feb 2000;27(2):481-4. [[Medline]](http://reference.medscape.com/medline/abstract/10685817).
49. Fricton JR. Myofascial pain syndrome. Neurol Clin. May 1989;7(2):413-27. [[Medline]](http://reference.medscape.com/medline/abstract/2657382).
50. Gandhavadi B. Bilateral piriformis syndrome associated with dystonia musculorum deformans. Orthopedics. Mar 1990;13(3):350-1. [[Medline]](http://reference.medscape.com/medline/abstract/2315224).
51. Girdler NM. Uses of botulinum toxin. Lancet. Mar 29 1997;349(9056):953. [[Medline]](http://reference.medscape.com/medline/abstract/9093271).
52. Göbel H, Heinze A, Heinze-Kuhn K, et al. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. Apr 2001;91(3):195-9. [[Medline]](http://reference.medscape.com/medline/abstract/11275374).
53. Hallin RP. Sciatic pain and the piriformis muscle. Postgrad Med. Aug 1983;74(2):69-72. [[Medline]](http://reference.medscape.com/medline/abstract/6878094).
54. [Best Evidence] Hayton MJ, Santini AJ, Hughes PJ, et al. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am. Mar 2005;87(3):503-7. [[Medline]](http://reference.medscape.com/medline/abstract/15741614).
55. Hesse S, Jahnke MT, Luecke D, et al. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. Dec 1 1995;201(1):37-40. [[Medline]](http://reference.medscape.com/medline/abstract/8830307).
56. Jankiewicz JJ, Hennrikus WL, Houkom JA. The appearance of the piriformis muscle syndrome in computed tomography and magnetic resonance imaging. A case report and review of the literature. Clin Orthop. Jan 1991;(262):205-9. [[Medline]](http://reference.medscape.com/medline/abstract/1984918).
57. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. Apr 25 1991;324(17):1186-94. [[Medline]](http://reference.medscape.com/medline/abstract/2011163).
58. Julsrud ME. Piriformis syndrome. J Am Podiatr Med Assoc. Mar 1989;79(3):128-31. [[Medline]](http://reference.medscape.com/medline/abstract/2724111).
59. Keizer SB, Rutten HP, Pilot P, et al. Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. Clin Orthop Relat Res. Aug 2002;125-31. [[Medline]](http://reference.medscape.com/medline/abstract/12151889).
60. King JC, Goddard MJ. Pain rehabilitation. 2. Chronic pain syndrome and myofascial pain. Arch Phys Med Rehabil. May 1994;75(5 Spec No):S9-14. [[Medline]](http://reference.medscape.com/medline/abstract/7910454).
61. LaBan MM, Meerschaert JR, Taylor RS. Electromyographic evidence of inferior gluteal nerve compromise: an early representation of recurrent colorectal carcinoma. Arch Phys Med Rehabil. Jan 1982;63(1):33-5. [[Medline]](http://reference.medscape.com/medline/abstract/7055417).
62. Lalli F, Gallai V, Tambasco N, et al. Botulinum A toxin versus lidocaine in the treatment of myofascial pain: a double-blind randomized study. International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. 1999;72.
63. Lang AM. Botulinum toxin therapy for myofascial pain disorders. Curr Pain Headache Rep. Oct 2002;6(5):355-60. [[Medline]](http://reference.medscape.com/medline/abstract/12207848).
64. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil. Mar 2003;84(3 Suppl 1):S69-73; quiz S74-5. [[Medline]](http://reference.medscape.com/medline/abstract/12708561).
65. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil. Mar 2004;83(3):198-202. [[Medline]](http://reference.medscape.com/medline/abstract/15043354).
66. McClaflin RR. Myofascial pain syndrome. Primary care strategies for early intervention. Postgrad Med. Aug 1994;96(2):56-9, 63-6, 69-70 passim. [[Medline]](http://reference.medscape.com/medline/abstract/8041685).
67. Mellanby J. Comparative activities of tetanus and botulinum toxins. Neuroscience. Jan 1984;11(1):29-34. [[Medline]](http://reference.medscape.com/medline/abstract/6143282).
68. Monsivais JJ, Monsivais DB. Botulinum toxin in painful syndromes. Hand Clin. Nov 1996;12(4):787-9. [[Medline]](http://reference.medscape.com/medline/abstract/8953298).
69. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. Feb 1994;32(1):26-8. [[Medline]](http://reference.medscape.com/medline/abstract/8136334).
70. National Institutes of Health. Consensus conference. Clinical use of botulinum toxin. National Institutes of Health. Conn Med. Aug 1991;55(8):471-7. [[Medline]](http://reference.medscape.com/medline/abstract/1935069).
71. Noftal F. The piriformis syndrome. Can J Surg. Jul 1988;31(4):210. [[Medline]](http://reference.medscape.com/medline/abstract/3390766).
72. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. Jan 2006;22(1):90-6. [[Medline]](http://reference.medscape.com/medline/abstract/16340597).
73. Pacchetti C, Albani G, Martignoni E, et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. May 1995;10(3):333-6. [[Medline]](http://reference.medscape.com/medline/abstract/7651452).
74. Padberg M, de Bruijn SF, de Haan RJ, et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia. Aug 2004;24(8):675-80. [[Medline]](http://reference.medscape.com/medline/abstract/15265057).
75. Papadopoulos SM, McGillicuddy JE, Albers JW. Unusual cause of 'piriformis muscle syndrome'. Arch Neurol. Oct 1990;47(10):1144-6. [[Medline]](http://reference.medscape.com/medline/abstract/2222250).
76. Patel RK, Cianca J, Nguyen D. Therapeutic efficacy of botulinum toxin A trigger point injections for patients with myofascial pain. American Academy of Physical Medicine and Rehabilitation 61st Annual Assembly and Technical Exhibition. 1999.
77. Paulson GW, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord. Jul 1996;11(4):459. [[Medline]](http://reference.medscape.com/medline/abstract/8813236).
78. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. Mar 2000;85(1-2):101-5. [[Medline]](http://reference.medscape.com/medline/abstract/10692608).
79. Porta M, Loiero M, Gamba M, et al. Botulinum toxin type A versus steroid for the treatment of myofascial pain syndromes. International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. 1999;73.
80. Porta M, Maggioni G. Botulinum toxin (BoNT) and back pain. J Neurol. Feb 2004;251 Suppl 1:I15-8. [[Medline]](http://reference.medscape.com/medline/abstract/14991338).
81. [Best Evidence] Qerama E, Fuglsang-Frederiksen A, Kasch H, et al. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology. Jul 25 2006;67(2):241-5. [[Medline]](http://reference.medscape.com/medline/abstract/16864815).
82. Raj PP. Botulinum toxin therapy in pain management. Anesthesiol Clin North America. Dec 2003;21(4):715-31. [[Medline]](http://reference.medscape.com/medline/abstract/14719715).
83. Reilich P, Fheodoroff K, Kern U, et al. Consensus statement: botulinum toxin in myofascial [corrected] pain. J Neurol. Feb 2004;251 Suppl 1:I36-8.
84. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol. Feb 2004;251 Suppl 1:I12-4. [[Medline]](http://reference.medscape.com/medline/abstract/14991337).
85. Relja MA. Botulinum toxin type A in the treatment of tension-type headache. International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. 1999;67.
86. Rollnik JD, Dengler R. Botulinum toxin (DYSPORT) in tension-type headaches. Acta Neurochir Suppl. 2002;79:123-6. [[Medline]](http://reference.medscape.com/medline/abstract/11974977).
87. Rollnik JD, Tanneberger O, Schubert M. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache. Apr 2000;40(4):300-5. [[Medline]](http://reference.medscape.com/medline/abstract/10759934).
88. Ron Y, Avni Y, Lukovetski A, et al. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum. Dec 2001;44(12):1821-6. [[Medline]](http://reference.medscape.com/medline/abstract/11742168).
89. Rosales RL, Arimura K, Takenaga S, et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve. Apr 1996;19(4):488-96. [[Medline]](http://reference.medscape.com/medline/abstract/8622728).
90. Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. Jul-Aug 2001;41(7):658-64. [[Medline]](http://reference.medscape.com/medline/abstract/11554953).
91. Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. May 2004;109(1-2):110-4. [[Medline]](http://reference.medscape.com/medline/abstract/15082132).
92. Schulte-Mattler WJ, Opatz O, Blersch W, et al. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J Neurol Sci. May 2 2007;[[Medline]](http://reference.medscape.com/medline/abstract/17481662).
93. Schulte-Mattler WJ, Wieser T, Aierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. International conference 1999: basic and therapeutic aspects of botulinum and tetanus toxins. Vol 68. 1999.
94. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res. May 26 1999;4(5):183-6. [[Medline]](http://reference.medscape.com/medline/abstract/10336407).
95. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. Sep 1993;16(9):964-9. [[Medline]](http://reference.medscape.com/medline/abstract/8355728).
96. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. Dec 2002;6(6):460-9. [[Medline]](http://reference.medscape.com/medline/abstract/12413405).
97. Sheean GL, Murray NM, Marsden CD. Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp. Lancet. Jul 15 1995;346(8968):154-6. [[Medline]](http://reference.medscape.com/medline/abstract/7603232).
98. Sherman S, Kopecky KK, Brashear A, et al. Percutaneous celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis. J Clin Gastroenterol. Jun 1995;20(4):343-4. [[Medline]](http://reference.medscape.com/medline/abstract/7665834).
99. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. Jun 2000;40(6):445-50. [[Medline]](http://reference.medscape.com/medline/abstract/10849039).
100. Simons DG, Travell JG. Myofascial origins of low back pain. 3. Pelvic and lower extremity muscles. Postgrad Med. Feb 1983;73(2):99-105, 108. [[Medline]](http://reference.medscape.com/medline/abstract/6823467).
101. Simons DG, Travell JG, Simons LS. Travell & Simons' Myofascial pain and Dysfunction: The Trigger Point Manual. Baltimore, Md: Lippincott, Williams & Wilkins; 1999:33.
102. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S147-54. [[Medline]](http://reference.medscape.com/medline/abstract/12569962).
103. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. Sep 2004;44(8):801-5. [[Medline]](http://reference.medscape.com/medline/abstract/15330827).
104. Smuts JA, Smuts HM, Baker MK, et al. Botulinum toxin type A as prophylactic treatment in chronic tension-type headache. International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. 1999;68.
105. Snyder-Mackler L, Bork C, Bourbon B, et al. Effect of helium-neon laser on musculoskeletal trigger points. Phys Ther. Jul 1986;66(7):1087-90. [[Medline]](http://reference.medscape.com/medline/abstract/3523551).
106. Solheim LF, Siewers P, Paus B. The piriformis muscle syndrome. Sciatic nerve entrapment treated with section of the piriformis muscle. Acta Orthop Scand. Feb 1981;52(1):73-5.
107. Steiner C, Staubs C, Ganon M, et al. Piriformis syndrome: pathogenesis, diagnosis, and treatment. J Am Osteopath Assoc. Apr 1987;87(4):318-23. [[Medline]](http://reference.medscape.com/medline/abstract/3583849).
108. Sycha T, Kranz G, Auff E, et al. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol. Feb 2004;251 Suppl 1:I19-30.
109. Thorsen H, Gam AN, Svensson BH, et al. Low level laser therapy for myofascial pain in the neck and shoulder girdle. A double-blind, cross-over study. Scand J Rheumatol. 1992;21(3):139-41. [[Medline]](http://reference.medscape.com/medline/abstract/1604252).
110. Van Daele DJ, Finnegan EM, Rodnitzky RL, et al. Head and neck muscle spasm after radiotherapy: management with botulinum toxin A injection. Arch Otolaryngol Head Neck Surg. Aug 2002;128(8):956-9.
111. Vernick SH. Comments on Cheshire et al. (PAIN, 59 (1994) 65-69). Pain. Aug 1995;62(2):249. [[Medline]](http://reference.medscape.com/medline/abstract/8545152).
112. Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology. Oct 14 2003;61(7):940-4. [[Medline]](http://reference.medscape.com/medline/abstract/14557564).
113. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain. Dec 2001;94(3):255-60. [[Medline]](http://reference.medscape.com/medline/abstract/11731062).
114. Winner P, Cady R, Chun EM, et al. A multi-center double-blind, placebo-controlled trial of two dosages of botulinum toxin type A in the prophylactic treatment of migraine. International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. 1999;68.
115. Zermann D, Ishigooka M, Schubert J, et al. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?. Eur Urol. Oct 2000;38(4):393-9. [[Medline]](http://reference.medscape.com/medline/abstract/11025376).